duration and quality of postoperative pain control with intercostal nerve blockade after open cholecystectomies
Conditions
Interventions
Trade Name: Catapressan
Product Name: Catapressan
Pharmaceutical Form: Injection*
Pharmaceutical form of the placebo: Injection*
Route of administration of the placebo: Parenteral use (Noncurrent)
Tr
Sponsors
VO Anesthesia/ICU Lunds University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: ·Patients with the diagnosis of cholelithiasis. ·Patients fulfilling criteria for ASA (American Society of Anesthesiologists) classification 1-3; see appendix ·Patients scheduled for either open cholecystectomies or reversed from laparoscopic to open cholecystectomies. ·Signed informed consent by patient. · Age 18-75 years. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Preoperative exclusion criteria: ·Chronic pain or ingestion of pain modulating drugs on a regular basis preoperatively. ·Pregnancy ·Non-tolerance or contraindications to local anesthetics, clonidin, adrenalin or opioids. ·Cognitive or linguistic problems precluding effective postoperative pain evaluation. ·Patients with a body weight less than 50 kg or exceeding > 150 kg. ·Dermatitis or infection overlying injection sites or anatomical reason contraindicating an intercostal blockade. ·Chronic Obstructive Pulmonary Disease or other criteria which increase the risk of significant pneumothorax after intercostal blockade. Intraoperative exclusion criterias: ·Planned laparoscopic surgery completed without conversion to open cholecystectomi. ·Unforeseen complication of anesthetic management requiring prolonged intubation postoperatively. ·Surgical complication with surgical time of > 2 hours, injuries to choledochus or spleen intraoperatively. ·The need for intraabdominal or intrathoracal drainage postoperatively.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate quality and duration of intercostal nerve blockades with the addition of clonidin to the standard infiltration with marcain/adrenalin.;Secondary Objective: patient satisfaction, complications;Primary end point(s): Time to first analgesic injection and opioid consumption postoperatively. | — |
Countries
Sweden
Outcome results
None listed